Cadence Neuroscience
Sammamish, US · Founded 2017 · Delaware corporation · 21 employees on LinkedIn · 9 known investors
Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy. The medical device is designed to be adaptable to individual patient needs and was developed in collaboration with Mayo Clinic.
Founders & leadership
Cadence Neuroscience was founded in 2017 by Kent Leyde.
KL
Kent LeydeFounder
WD
Warren Douglas SheffieldNamed on SEC filing
Investors · 9
JAZZ Venture Partners✓ verifiedSan Francisco · $100K – $20M
Lumira Ventures✓ verifiedToronto · $1M – $10Mvia Gerry Brunk · board
Angelini VenturesRome
F-Prime CapitalCambridge · $3M – $10M
Iaso VenturesCambridge
Also in the syndicate · 4
Angelini Lumira Biosciences FundleadLivaNova USAMayo ClinicSpectrum Financial Services
Reported raises · per SEC filings
Form D private placements$29M disclosed across 2 of 3 rounds · 2017–2023
▶$26MraisedFeb 2023 · 7 investors · BiotechnologyRule 506(b)
▶$26MraisedFeb 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John HarrisDirector
- Kevin ChuDirector
- Kent LeydeExecutive Officer, Director
- Gerry BrunkDirector
- Warren Douglas SheffieldExecutive Officer
- Offering amount
- $26M
- Amount sold
- $26M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedSep 2019 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kent LeydeExecutive Officer, Director, Promoter
- Warren Douglas SheffieldExecutive Officer, Director, Promoter
- Andrew FirlikDirector
- John HarrisDirector
- Offering amount
- $15M
- Amount sold
- $3M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶Undisclosed amountofferedJul 2017 · 1 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJul 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kent LeydeExecutive Officer, Director, Promoter
- Warren Douglas SheffieldExecutive Officer, Director, Promoter
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Cadence Neuroscience do?
- Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy. The medical device is designed to be adaptable to individual patient needs and was developed in collaboration with Mayo Clinic.
- Who founded Cadence Neuroscience?
- Cadence Neuroscience was founded by Kent Leyde in 2017.
- Who are Cadence Neuroscience's investors?
- Cadence Neuroscience's investors include JAZZ Venture Partners, Lumira Ventures, Angelini Ventures, F-Prime Capital, Iaso Ventures.
- How much funding has Cadence Neuroscience raised?
- Cadence Neuroscience has disclosed $29M raised across 2 of its 3 known rounds.
- Where is Cadence Neuroscience headquartered?
- Cadence Neuroscience is headquartered in Sammamish, US.